Mutations in CIC, DMD and PHOX2B Activate the RAS-MAPK Pathway in Neuroblastoma and Activation of this Pathway Causes Tumor Progression

被引：0
|
作者：
Eleveld, T. F. [1 ,2 ]
Schild, L. [1 ]
Koster, J. [2 ]
Zwijnenburg, D. A. [2 ]
Alles, L. [1 ]
Ebus, M. E. [1 ]
Volckmann, R. [2 ]
Tijtgat, G. A. [3 ]
van Sluis, P. [2 ]
Caron, H. N. [3 ]
Versteeg, R. [2 ]
Molenaar, J. J. [1 ]
机构：
[1] Princess Maxima Ctr Childhood Oncol, Dept Translat Res, Utrecht, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Oncogen, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Oncol, Amsterdam, Netherlands
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AW-08
引用
下载
收藏
页码：S6 / S6
页数：1
相关论文
共 31 条
  • [1] Mutations in CIC, DMD and PHOX2B Activate the RAS-MAPK Pathway in Neuroblastoma and Activation of this Pathway Causes Tumor Progression
    Eleveld, T. F.
    Schild, L.
    Koster, J.
    Zwijnenburg, D. A.
    Alles, L.
    Ebus, M. E.
    Volckmann, R.
    Tijtgat, G. A.
    van Sluis, P.
    Caron, H. N.
    Versteeg, R.
    Molenaar, J. J.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S40 - S40
  • [2] RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma
    Eleveld, Thomas F.
    Schild, Linda
    Koster, Jan
    Zwijnenburg, Danny A.
    Alles, Lindy K.
    Ebus, Marli E.
    Volckmann, Richard
    Tijtgat, Godelieve A.
    van Sluis, Peter
    Versteeg, Rogier
    Molenaar, Jan J.
    CANCER RESEARCH, 2018, 78 (21) : 6297 - 6307
  • [3] Phox2B mutations and the Delta-Notch pathway in neuroblastoma
    van Limpt, V
    Chan, A
    Schramm, A
    Eggert, A
    Versteeg, R
    CANCER LETTERS, 2005, 228 (1-2) : 59 - 63
  • [4] Activation of the RAS-MAPK pathway in primary neuroblastoma tumors is associated with poor prognosis
    Eleveld, T. F.
    Schild, L.
    Ebus, M. E.
    van Sluis, P. G.
    Westerhout, E. M.
    Caron, H. N.
    Koster, J. J. B.
    Versteeg, R.
    Molenaar, J. J.
    CANCER RESEARCH, 2016, 76
  • [5] NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma
    Valencia-Sama, Ivette
    Ladumor, Yagnesh
    Kee, Lynn
    Adderley, Teresa
    Christopher, Gabriella
    Robinson, Claire M.
    Kano, Yoshihito
    Ohh, Michael
    Irwin, Meredith S.
    CANCER RESEARCH, 2020, 80 (16) : 3413 - 3423
  • [6] Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS/MAPK pathway
    Smits, Patrick J.
    Konczyk, Dennis J.
    Sudduth, Christopher L.
    Goss, Jeremy A.
    Greene, Arin K.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 529 (02) : 450 - 454
  • [7] Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase
    Science, 5277 (959):
  • [8] Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase
    Xing, J
    Ginty, DD
    Greenberg, ME
    SCIENCE, 1996, 273 (5277) : 959 - 963
  • [9] The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A
    Wilzen, Annica
    Nilsson, Staffan
    Sjoberg, Rose-Marie
    Kogner, Per
    Martinsson, Tommy
    Abel, Frida
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (03) : 697 - 705
  • [10] UBN2 promotes tumor progression via the Ras/MAPK pathway and predicts poor prognosis in colorectal cancer
    Ya-li Zhao
    Shen-Rong Zhong
    Shi-Hong Zhang
    Jia-Xin Bi
    Zhi-Yuan Xiao
    Shu-Yang Wang
    Hong-Li Jiao
    Dan Zhang
    Jun-Feng Qiu
    Ling-Jie Zhang
    Cheng-Mei Huang
    Xiao-Ling Chen
    Yan-Qing Ding
    Ya-Ping Ye
    Li Liang
    Wen-ting Liao
    Cancer Cell International, 19
1234